Do you routinely perform molecular profiling for potentially actionable targets in patients with advanced pancreatic cancer?

In our practice, we reserve the use of molecular broad NGS testing to our patients with metastatic disease, usually at time of first progression. Unfortunately not too many patients will have an actionable mutation, as the most common ones would be in KRAS and TP53.

CDKN2A is the most frequently ina...